Simulations Plus IncNASDAQ:SLP
- LAST PRICE47.9450
- TODAY'S CHANGE (%)-0.6750 (-1.3883%)
- Bid / Lots47.8200/ 2
- Ask / Lots48.0000/ 4
- Open / Previous Close48.0300 / 48.6200
- Day Range
- 52 Week Range
- Volume33,649
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLP |
|---|---|---|
| 09:32 ET | 533 | 48.03 |
| 09:39 ET | 500 | 48.29 |
| 09:56 ET | 615 | 47.68 |
| 09:57 ET | 210 | 47.7 |
| 09:59 ET | 100 | 47.3 |
| 10:06 ET | 200 | 47.01 |
| 10:08 ET | 1100 | 47.01 |
| 10:10 ET | 300 | 47.23 |
| 10:15 ET | 100 | 47.025 |
| 10:17 ET | 300 | 47.18 |
| 10:21 ET | 100 | 47.22 |
| 10:26 ET | 100 | 47.2 |
| 10:28 ET | 100 | 46.95 |
| 10:32 ET | 501 | 46.92 |
| 10:35 ET | 100 | 47.03 |
| 10:53 ET | 100 | 47.13 |
| 10:57 ET | 100 | 47.43 |
| 11:04 ET | 100 | 47.77 |
| 11:06 ET | 100 | 47.645 |
| 11:11 ET | 300 | 47.94 |
| 11:13 ET | 100 | 47.825 |
| 11:15 ET | 643 | 47.775 |
| 11:18 ET | 400 | 47.775 |
| 11:20 ET | 604 | 48.06 |
| 11:22 ET | 200 | 48.2 |
| 11:26 ET | 200 | 48.26 |
| 11:31 ET | 100 | 48.25 |
| 11:36 ET | 100 | 48.24 |
| 11:38 ET | 100 | 48.19 |
| 11:40 ET | 1825 | 47.8 |
| 11:42 ET | 161 | 47.8 |
| 11:44 ET | 100 | 47.97 |
| 11:51 ET | 500 | 47.8138 |
| 11:54 ET | 900 | 47.8 |
| 11:56 ET | 100 | 47.87 |
| 12:07 ET | 300 | 47.79 |
| 12:20 ET | 1188 | 47.8 |
| 12:21 ET | 300 | 47.905 |
| 12:27 ET | 100 | 47.99 |
| 12:32 ET | 100 | 47.91 |
| 12:36 ET | 100 | 47.99 |
| 12:38 ET | 100 | 47.99 |
| 12:39 ET | 200 | 48 |
| 12:41 ET | 200 | 48.05 |
| 12:56 ET | 300 | 47.95 |
| 12:57 ET | 200 | 47.83 |
| 01:21 ET | 210 | 47.895 |
| 01:24 ET | 137 | 47.9522 |
| 01:42 ET | 100 | 47.98 |
| 01:44 ET | 200 | 47.945 |
Yesterday
DJ Simulations Plus Is Maintained at Buy by Craig-Hallum, from 9:16AM ET on Thursday Jun 13, 2024 by Dow Jones
9:16AM ET on Thursday Jun 13, 2024 by Dow JonesDJ Simulations Plus Is Maintained at Outperform by Oppenheimer, from 7:26AM ET on Thursday Jun 13, 2024 by Dow Jones
7:26AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
*DJ QHP Capital-Backed Pro-ficiency Acquired By Simulations Plus SLP, from 8:58AM ET on Wednesday Jun 12, 2024 by Dow Jones
8:58AM ET on Wednesday Jun 12, 2024 by Dow JonesQHP Capital-Backed Pro-ficiency Acquired by Simulations Plus, from 8:58AM ET on Wednesday Jun 12, 2024 by Dow Jones
8:58AM ET on Wednesday Jun 12, 2024 by Dow JonesSimulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum, from 8:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
8:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Simulations Plus Inc | 971.7M | 92.7x | +3.18% |
Standard BioTools Inc | 836.0M | -2.2x | --- |
Coretag Inc | 1.1B | -13.1x | --- |
MaxCyte Inc | 517.5M | -13.9x | --- |
Pulse Biosciences Inc | 673.7M | -14.7x | --- |
Quanterix Corp | 555.7M | -13.9x | --- |
Company Information
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
Contact Information
- Headquarters
- 42505 10Th Street WestLANCASTER, CA, United States 93534-7059
- Phone
- 661-723-7723
- Fax
- 661-723-5524
Executives
- Chairman of the Board
- Walter Woltosz
- Chief Executive Officer
- Shawn O'Connor
- Chief Financial Officer, Chief Operating Officer, Secretary
- William Frederick
- President - PBPK, Regulatory Strategies, Cheminformatics Solutions
- John Dibella
- President - Clinical Pharmacology and Pharmacometric Services
- Jill Fiedler-Kelly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $971.7M |
|---|---|
Revenue (TTM) | $64.7M |
Shares Outstanding | 20.0M |
Dividend Yield | 0.50% |
Annual Dividend Rate | 0.2400 USD |
Ex-Dividend Date | 04-26-24 |
Pay Date | 05-06-24 |
Beta | 0.72 |
EPS | $0.52 |
Book Value | $8.53 |
P/E Ratio | 92.7x |
Price/Sales (TTM) | 15.0 |
Price/Cash Flow (TTM) | 66.1x |
Operating Margin | 12.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
